

**DNA vaccines encoding proteins from wild-type and attenuated canine distemper virus protect equally well against wild-type virus challenge**

Nielsen, L.; Jensen, Trine Hammer; Kristensen, B. ; Jensen, T. D. ; Karlskov-Mortensen, P. ; Lund, M. ; Aasted, B.; Blixenkrone-Møller, M.

*Published in:*  
Archives of Virology

*DOI (link to publication from Publisher):*  
[10.1007/s00705-012-1375-y](https://doi.org/10.1007/s00705-012-1375-y)

*Publication date:*  
2012

*Document Version*  
Early version, also known as pre-print

[Link to publication from Aalborg University](#)

*Citation for published version (APA):*  
Nielsen, L., Jensen, T. H., Kristensen, B., Jensen, T. D., Karlskov-Mortensen, P., Lund, M., Aasted, B., & Blixenkrone-Møller, M. (2012). DNA vaccines encoding proteins from wild-type and attenuated canine distemper virus protect equally well against wild-type virus challenge. *Archives of Virology*, 157(10), 1887-1896.  
<https://doi.org/10.1007/s00705-012-1375-y>

**General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal -

**Take down policy**

If you believe that this document breaches copyright please contact us at [vbn@aub.aau.dk](mailto:vbn@aub.aau.dk) providing details, and we will remove access to the work immediately and investigate your claim.



# DNA vaccines encoding proteins from wild-type and attenuated canine distemper virus protect equally well against wild-type virus challenge

Line Nielsen · Trine Hammer Jensen · Birte Kristensen ·  
Tove Dannemann Jensen · Peter Karlskov-Mortensen ·  
Morten Lund · Bent Aasted · Merete Blixenkrone-Møller

Received: 24 February 2012 / Accepted: 7 May 2012  
© Springer-Verlag 2012

**Abstract** Immunity induced by DNA vaccines containing the hemagglutinin (H) and nucleoprotein (N) genes of wild-type and attenuated canine distemper virus (CDV) was investigated in mink (*Mustela vison*), a highly susceptible natural host of CDV. All DNA-immunized mink seroconverted, and significant levels of virus-neutralizing (VN) antibodies were present on the day of challenge with wild-type CDV. The DNA vaccines also primed the cell-mediated memory responses, as indicated by an early increase in the number of interferon-gamma (IFN- $\gamma$ )-producing lymphocytes after challenge. Importantly, the wild-type and attenuated CDV DNA vaccines had a long-term protective effect against wild-type CDV challenge. The vaccine-induced immunity induced by the H and N genes from wild-type CDV and those from attenuated CDV was comparable. Because these two DNA vaccines were shown to protect equally well against wild-type virus challenge, it is suggested that the genetic/antigenic heterogeneity between vaccine strains and contemporary wild-type strains are unlikely to cause vaccine failure.

## Introduction

Canine distemper virus (CDV) is a member of the genus *Morbillivirus*, family *Paramyxoviridae*, that is closely related to measles virus (MeV), which infects humans [1]. These highly virulent contagious viruses cause severe diseases in their respective hosts worldwide, illustrating the need for the development of more efficacious and safer vaccines.

The lymphotropic CDV can cause a systemic, potentially fatal disease associated with severe immunosuppression in a broad range of domestic and wild carnivores including dog, mink and ferrets [2, 3]. Despite the use of attenuated live vaccines, outbreaks of distemper in both vaccinated and unvaccinated individuals have been reported [4–14].

The hemagglutinin (H) protein is the key determinant in viral entry, as it mediates the binding of the virus to the signalling lymphocyte activation molecule receptor (SLAM/CD150) at the surface of susceptible cells and thereby initiates virus infection [15, 16]. A possible reason for vaccine failure may be variation between the H proteins of the CDV strains used in vaccines and those of the currently circulating wild-type strains [9, 10, 17–19].

CDV strains worldwide can be divided into distinct geographically separated subtypes based on the H gene, namely, America-1, America-2, European, Arctic, Asia-1 and Asia-2 [17, 19–23]. The current and widely used CDV vaccines (such as Onderstepoort and Snyder Hill) are based on different attenuated strains isolated before 1960 and belong to the America-1 group [15]. It is uncertain whether the America-1 CDV strains still are circulating in the field, since they have not been seen in the last five decades [24]. The greatest diversity both genetically and antigenically is seen between field CDV isolates and the traditional vaccine

L. Nielsen (✉) · T. H. Jensen · B. Kristensen ·  
T. D. Jensen · P. Karlskov-Mortensen · M. Lund · B. Aasted  
Department of Veterinary Disease Biology, Faculty of Health  
and Medical Sciences, University of Copenhagen, Stigbøjlen 7,  
1870 Frederiksberg C, Copenhagen, Denmark  
e-mail: Lin@life.ku.dk

M. Blixenkrone-Møller  
Department of International Health, Immunology and  
Microbiology, Faculty of Health and Medical Sciences,  
University of Copenhagen, Copenhagen, Denmark

strains [10, 25–27]. The marked genetic and antigenic variation between wild-type CDV and vaccine CDV strains has been suggested to play a role in vaccine failures in animals immunized with attenuated live vaccine against circulating wild-type CDV [10, 19, 25, 27, 28]. Therefore, it is of high relevance to study the protective effects of DNA vaccines against wild-type CDV.

DNA vaccines have several advantages over attenuated live vaccines: (1) they contain no infectious components, while serious or even fatal infections can occur subsequent to vaccination with live CDV vaccines in some wildlife species [29–32], (2) they stimulate both long-lasting cellular and humoral immune response without any risk of reversion to virulence [33], and (3) they have the ability to induce immunity against morbilliviruses in offspring in the presence of maternal immunity [34–37]. A disadvantage of plasmid-DNA-based vaccines is the inefficient uptake of plasmid by cells because of inefficient delivery. This inefficient uptake results in less antigen production and the humoral immune response is thus limited. The first study of DNA vaccination in a natural host of CDV showed that dogs immunized with plasmids encoding the H, nucleoprotein (N) and fusion (F) genes were protected against severe clinical disease, while only a limited humoral response was induced [38]. The humoral response induces mainly virus-neutralizing (VN) antibodies directed against the H protein. A minor fraction of the VN antibodies are directed against the F protein, and these probably prevent fusion between the viral envelope and the host-cell membrane [39–43].

In earlier studies, it was demonstrated that vaccination with DNA vaccines consisting of the H and N genes from the attenuated CDV Onderstepoort strain conferred solid cross-protection against infection of mink with virulent wild-type CDV strains [44–46]. The studies showed that the vaccine-specific VN antibody and cell-mediated responses that were induced provided robust protection against disease development in both adult and young mink [44–46].

In the present study, a new DNA vaccine, containing plasmids encoding the H, N and F genes from wild-type CDV derived from a distemper outbreak in partly vaccinated dogs in Denmark in 1991 (DK91) [5], was developed. A possible explanation for vaccine failure found during the Danish distemper outbreak could be interference by maternally-derived antibodies [5]. Another explanation could be inappropriate vaccination due to immunization immediately before or after viral exposure.

In this study, the immunogenicity of a novel wild-type DNA vaccine and a DNA vaccine encoding the H and N genes from the attenuated Onderstepoort strain was investigated by challenge inoculation with the same wild-type CDV used to create the wild-type DNA vaccine. The DK91 wild-type CDV strain induces massive lymphocyte-associated viremia, lymphopenia and multisystemic

infection in mink [46, 47]. Viremia and lymphopenia are characteristic for virulent CDV infections in its highly susceptible natural hosts [44, 47–49]. Long-term protective immunity was investigated here, as the challenge inoculation was performed 28 weeks after the last immunization with the DNA vaccines.

## Materials and methods

### Experimental animals

A total of twenty CDV-seronegative female wild-type mink (*Mustela vison*), 10–12 months of age, were purchased from Østergård Farm (Roskilde, Denmark). The mink had no records of Aleutian mink disease virus or mink enteritis virus. Experimental procedures were in accordance with the requirements of the Danish Animal Care and Ethics Committee.

### Viruses

The wild-type CDV strain DK91B (in short, DK91) was derived from a dog with acute fatal distemper during an epidemic in Denmark in 1991 [5]. This wild-type isolate was propagated by passage of organ homogenates three times in mink before use in the present study as challenge inoculum. Spleen homogenates of 10 % or 20 % (w/v) were prepared in RPMI1640, cleared by centrifugation at  $1500 \times g$  for 10 minutes and frozen in aliquots at  $-80^{\circ}\text{C}$ . The Danish wild-type isolates DK91 and DK91C (from another acute fatal clinical case from the 1991 epidemic in Denmark) were used to produce the wild-type DNA vaccine [5, 50]. In a similar way, CDV-negative spleen homogenates were prepared from uninfected animals. The Onderstepoort strain of CDV was used for virus neutralization (VN) test.

### Preparation of DNA vaccines

cDNAs encoding CDV DK91 H, N, and F proteins were subcloned into the eukaryotic expression plasmid vector pVR1012 (Vical, San Diego, CA, USA), which contains the cytomegalovirus (CMV) promoter [51]. To facilitate making these constructs, site-directed mutagenesis was used to introduce SalI sites at the 5' ends and BglII at the 3' ends of the H and F cDNAs, and SalI sites at the 5' ends and XbaI sites at the 3' ends of N cDNA. The resulting plasmids were named pVRCDV-H (1890 bp), pVRCDV-N (1615 bp) and pVRCDV-F (2204 bp). The inserts were sequenced using an ABI Prism BigDye Terminator Cycle Sequencing Ready Reaction Kit (Perkin Elmer) and analyzed in a Prism 310 Genetic Analyzer (Applied Biosystems). For confirmation of expression, pVRCDV-H, pVRCDV-N and pVRCDV-F

were introduced by transfection into Vero cells (SuperFect Transfection Reagent, QIAGEN). Expression of the corresponding CDV proteins was confirmed by using an immunofluorescence assay as described previously [25].

The plasmids pCDV-H and pCDV-N consisted of the expression plasmid vector pVIJ (p) [52] containing the insert of the H gene (1815 bp) or the N gene (1573 bp) of the CDV Onderstepoort strain [44, 46, 53]. The expression from pCDV-H and pCDV-N has been described and confirmed previously [44, 53]. The plasmids were purified using an EndoFree Plasmid Giga Kit according to the supplier's protocol (QIAGEN) with a few modifications [44, 53]. Purified DNA plasmids were dissolved in phosphate-buffered saline to a final concentration of 1 µg/µl.

#### Administration of DNA vaccines


Immunizations were carried out under anaesthesia with ketamine hydrochloride (15 mg/kg) and xylazine hydrochloride (1 mg/kg) (Ketaminol Vet. and Narcoxyl Vet., Intervet, Denmark), which were administered intramuscularly. The vaccine dose was 800 µg of each plasmid. One third of the dose was administered intradermally, and the rest, intramuscularly as described previously [44]. Four mink received the pCDV-H and pCDV-N plasmids (Fig. 1). Four received a mixture of pVRCDV-H and pVRCDV-N plasmids, and four received a mixture of pVRCDV-H, pVRCDV-N and pVRCDV-F plasmids. Two were given the empty plasmid vector pVR1012 (pVR), and two did not receive any plasmid (non-vaccinated). The mink were vaccinated four times at three-week intervals (Fig. 1).

#### Experimental infection

Challenge inoculation was performed 28 weeks after the last immunization. Fourteen mink were inoculated with  $1.6 \times 10^5$  TCID<sub>50</sub> per ml of the DK91 wild-type CDV strain homogenate, and three control animals were inoculated with non-infectious spleen homogenate (Fig. 1). Under anaesthesia, 1 ml of the homogenate suspension 10 % (w/v) was dripped into each conjunctiva and nostril and 4 ml of the 20 % (w/v) homogenate was injected intraperitoneally. Two days later, the animals were given a second dose of 1 ml of the 10 % spleen homogenate in the conjunctiva and nostrils. They were then examined daily for clinical signs of disease throughout the challenge period, and finally, eight weeks after challenge, they were anesthetized and then euthanized with barbiturate.

#### Mink specimens

Blood samples for serum collection and flow cytometric analysis were drawn by puncture of the vena cephalica



Vaccine	Challenge	No. of mink
pCDV-H/-N	+	<i>n</i> = 4(3)*
pVRCDV-H/-N	+	<i>n</i> = 4
pVRCDV-H/-N/-F	+	<i>n</i> = 4(3)*
pVR/non-vaccinated	+	<i>n</i> = 4
Control	-	<i>n</i> = 3

**Fig. 1** Four mink were vaccinated with a mixture of plasmid vectors pVIJ (p) expressing the hemagglutinin (H) and nucleoprotein (N) proteins of the Onderstepoort strain of CDV (pCDV-H/-N). Eight were vaccinated with plasmid vectors pVR1012 (pVR) expressing H, N proteins and with or without fusion (F) protein of the wild-type CDV strain DK91 (pVRCDV-H/-N/-F or pVRCDV-H/-N). \*One mink in the pVRCDV-H/-N/-F group and one in the pCDV-H/-N group died unexplainably just before the last vaccination and around five months later, respectively, which reduced the number of animals to three in each of those groups. Two animals received empty pVR, and two were left unvaccinated (pVR/non-vaccinated). The animals were vaccinated four times at three-week intervals and challenged (day 0 and 2) with the wild-type strain DK91 28 weeks after the last vaccination. Three mink were included as uninfected controls

accessoria [54]. Tissues samples were transported on dry ice and stored at  $-80^{\circ}\text{C}$  until two-step RT-PCR were performed.

#### Virus neutralization (VN) test

VN antibody determinations were performed in Vero cell cultures using the TCID<sub>50</sub> format microtiter assay and the Vero-cell-adapted Onderstepoort strain as described previously [46]. The titers were calculated by the Reed and Munch method [43].

#### Two-step RT-PCR assay

Total RNA preparations were isolated using RNA Now (Ozyme, Biogentex, St Quentin Yvelines, France) from 80–100 mg homogenised tissues (brain tissue was taken from the cranial and caudal part of cerebrum and cerebellum, mesenteric lymph node, spleen and lung). Two-step RT-PCR reactions were performed as described previously [46]. Briefly, cDNA was synthesised from 1 µg of total RNA using reverse transcriptase and random priming with hexamers (Advantage RT-for-PCR Kit, Clontech, Paulo Alto, CA, USA). PCR was performed with the “universal” primer pair against the phosphoprotein gene first described by Barrett et al. [55]. As a control for the RNA extraction, primers for cellular glyceraldehyde-3-phosphate

dehydrogenase were used. The limit of detection of this assay was 0.03 TCID<sub>50</sub> in 1 µg of total RNA [46].

#### Flow cytometric analysis of peripheral blood leukocytes

Flow cytometric analysis was carried out on a FACS Calibur flow cytometer (Becton Dickinson, CA, USA) as described previously [46]. In a forward-scatter-versus-side-scatter diagram, populations of lymphocytes, monocytes and granulocytes were gated and quantified ( $2 \times 10^3$  peripheral blood leukocytes were collected). The absolute leukocyte counts were performed using TruCount quantification beads (Becton Dickinson) [56]. Within the lymphocyte/monocyte gates,  $2 \times 10^4$  cells were collected for single-cell cytokine production. An additional  $1 \times 10^4$  cells were collected for detection of intracellular CDV-N antigen. The percentages of cytokine-positive cells were calculated after subtraction of positive signals from isotype-matched immunoglobulin control preparations. A cross-reacting monoclonal antibody to bovine interferon gamma (IFN- $\gamma$ ) (catalogue no. MCA 1783, Serotec, Oxford, United Kingdom) was used [57]. A monoclonal antibody against the CDV-N protein was used for viral antigen detection [43]. A rabbit antibody to mouse IgG F(ab')<sub>2</sub> fragments conjugated to fluorescein isothiocyanate (code no. F0313, DakoCytomation) was used as secondary antibody. For statistical evaluations, Student's *t*-test was used. All *P*-values were two-tailed and were considered statistically significant when the associated probability was less than 0.05.

#### Excluded animals

One control mink exhibited extraordinarily low lymphocyte counts on the day of inoculation with non-infectious organ homogenate. The reason for the low lymphocyte count remained unknown, and the animal was excluded from the trial. Another mink that had received empty plasmid (pVR) had a high lymphocyte count on the day of challenge inoculation and was also excluded.

## Results


#### Virus-neutralizing (VN) antibody responses after DNA immunization

Mink were immunized four times with plasmids encoding the CDV genes of the Onderstepoort strain (pCDV-H/-N) or with the plasmids encoding CDV genes of the wild-type DK91 strain (pVRCDV-H/-N/-F) as summarized in Fig. 1. Already after two immunizations, all animals vaccinated with the pCDV-H and -N had medium levels of

serum VN antibodies (average titer: 1.9 log<sub>10</sub>; Fig. 2). In all DNA-immunized animals, VN antibodies were measured six weeks after the last immunization, corresponding to 22 weeks before challenge (-22w in Fig. 2). The VN antibody titers remained constant without any significant variations until challenge with the wild-type CDV strain DK91. The control animals did not develop any detectable serum VN antibodies during the experimental period (Fig. 2).

#### Long-term protective effects of DNA immunization in mink

Mink were challenged intraperitoneally and on the conjunctival and nasal mucosa 28 weeks after the last immunization on days 0 and 2 (Fig. 1). The wild-type CDV strain DK91 caused a mild virulent infection. The animals in the pVR/non-vaccinated group became lymphopenic (defined in the legend to Table 1) and viremic (defined here as positive for cell-associated CDV-N antigen) during the first weeks after challenge (Figs. 3, 4; Table 1). Subsequent multisystemic infection developed with the presence of CDV RNA in the lymphoid system (lymph node and spleen), lung, cerebrum and cerebellum (Table 1). Thus, DNA immunization of mink had a long-term protective effect against lymphopenia, viremia and multisystemic infection.



**Fig. 2** CDV-specific virus-neutralizing (VN) antibody response induced by DNA vaccination and after challenge (arrows) with the DK91 wild-type strain. Blood samples from vaccinated mink (pCDV-H/-N: *n* = 3; pVRCDV-H/-N: *n* = 4; pVRCDV-H/-N/-F: *n* = 3), pVR/non-vaccinated mink (*n* = 4) and uninfected controls (*n* = 3) were collected on the indicated days (d) and weeks (w). The horizontal dotted line indicate log<sub>10</sub> = 2, which equals a neutralizing titer of 100. The values shown are geometric means  $\pm$  standard deviation. The x-axis is not drawn to scale



## Humoral and cellular immune responses after challenge with wild-type CDV

To evaluate the humoral and cellular immune responses after challenge, we measured the titer of VN antibodies and the percentages of IFN- $\gamma$ -producing lymphocytes in the peripheral blood. The results showed that all of the DNA-vaccinated animals exhibited a memory VN antibody response that was already present five days after challenge (between 1.8- and 2.0-fold increase; Fig. 2). The VN antibody titers remained above 100 until the end of the experiment (Fig. 2). Titers above 100 are considered indicative of protection [49, 58]. Serum VN antibodies in pVR/non-vaccinated mink were not detectable until two weeks after challenge, and the average serum VN antibody titers remained below or at 100 (Fig. 2).

The DNA vaccines were also found to prime the cell-mediated memory responses, as an early increase in the number of IFN- $\gamma$ -producing lymphocytes was measured by flow cytometry (Fig. 5). Interestingly, the early response of IFN- $\gamma$ -producing lymphocytes found in DNA-vaccinated animals (Fig. 5a, b; Table 1) was statistically significant when compared to the pVR/non-vaccinated group (Fig. 5c and Table 1). In all DNA-vaccinated animals, we detected

an average of 10 % or more IFN- $\gamma$ -producing lymphocytes on days 6 and 9 after challenge, while less than 3 % IFN- $\gamma$  producing lymphocytes were found in the pVR/non-vaccinated group (Fig. 5 and Table 1). In the pVR/non-vaccinated animals, levels of IFN- $\gamma$  producing lymphocytes comparable to the ones found in the immunized animals appeared much later, on days 21 and 28 after challenge (Fig. 5c and Table 1). Less than 1 % IFN- $\gamma$ -producing lymphocytes were found in the pVR/non-vaccinated mink on day 6 after challenge, at the time when the animals were lymphopenic and viremic. Uninfected control animals were included to estimate the background level of IFN- $\gamma$ -producing lymphocytes. The average background level was 4.0 % to 9.5 % IFN- $\gamma$ -producing lymphocytes throughout the experimental period (Fig. 5d and Table 1).

## Discussion

The aim of the present study was to investigate the immunogenic and protective effect of DNA vaccines based on different CDV strains against canine distemper in a natural host. CDV strains isolated from vaccinated dogs with CDV-related disease have been found to be distinguishable from

**Table 1** Long-term protective capacity of the DNA vaccines against CDV

Group	Lymphopenia <sup>a</sup>						Viremia <sup>b</sup>					CDV RNA in <sup>c</sup>					IFN- $\gamma$ <sup>d</sup>					
	after challenge						after challenge										after challenge					
	6d	9d	2w	3w	4w	8w	6d	9d	2w	3w	4w	Lymph node	Spleen	Lung	Cerebrum	Cerebellum	0d	6d	9d	2w	3w	4w
pCDV-H/-N	□	□	□	□	□	□	□	□	□	□	□	0/3	0/3	0/3	0/3	0/3	■	■	■	■	■	■
pVRCDV-H/-N	□	□	□	□	□	□	□	□	□	□	□	0/4	0/4	0/4	0/4	0/4	■	■	■	■	■	■
pVRCDV-H/-N/-F	□*	□	□	□	□	□	---	---	---	---	---	0/3	0/3	0/3	0/3	0/3	-	-	-	-	-	-
pVR/non-vaccinated	■	■	□	□	□	□	■	■	■	■	■	4/4	4/4	3/4	2/4	1/4	■	□	□	■	■	■
Control	□	□	□	□	□	□	□	□	□	□	□	0/3	0/3	0/3	0/2	0/2	■	■	■	■	■	■

Data are expressed as number of animals testing positive/number tested. Box symbols are explained below. “-”, not tested


The mink were challenge 28 weeks after the last immunization and euthanized 8 weeks after challenge with the wild-type DK91 strain. Overt clinical signs were not observed

<sup>a</sup> Lymphocytes were quantitated by flow cytometry at days 0, 6 and 9 and weeks 2, 3, 4 and 8 after CDV challenge. Each box represents the average counts for the group of mink. Grey boxes indicate a >2.2-fold decrease in lymphocyte count when compared to the pre-inoculation counts (day 0). White boxes represent a  $\leq$ 2.2-fold decrease. \*One mink vaccinated with pVRCDV-H, -N, -F had transient lymphopenia similar to that observed in the pVR/non-vaccinated group


<sup>b</sup> The presence of viral N-antigen in the peripheral blood lymphocytes was analyzed by flow cytometry at days 0, 6 and 9 and weeks 2, 3 and 4 after challenge. Black boxes indicate  $\geq$ 20 % positive lymphocytes, grey boxes indicate  $>$ 5 % positive lymphocytes, striped boxes indicate  $\leq$ 5 % positive lymphocytes, and white boxes indicate that viremia was not detected (defined as less than 3 % positive lymphocytes). Each box represents individual animals

<sup>c</sup> The presence of viral RNA was tested in various tissues post-mortem by fragment amplification of CDV phosphoprotein RNA in a two-step RT-PCR

<sup>d</sup> Percentage of IFN- $\gamma$ -producing lymphocytes at days 0, 6 and 9 and weeks 2, 3 and 4 after challenge. Black boxes indicate  $\geq$ 10 % IFN- $\gamma$ -positive lymphocytes, grey boxes indicate  $<$ 10 % IFN- $\gamma$ -positive lymphocytes, and white boxes indicate  $<$ 1 % IFN- $\gamma$ -positive lymphocytes. Each box represents the average percentage for each group of animals



**Fig. 3** (a) Lymphocyte levels in vaccinated mink (pCDV-H/-N;  $n = 3$ ; pVRCDV-H/-N/-F;  $n = 3$ ; pVRCDV-H/-N;  $n = 4$ ), pVR/non-vaccinated mink ( $n = 3$ ) and uninfected controls ( $n = 3$ ) were measured by flow cytometry on the indicated days (d) and weeks (w). Since the lymphocyte counts varied, the lymphocyte counts from the individual animals were compared to their pre-inoculated counts on day 0 as illustrated in Table 1. (b) Forward-scatter-versus-side-scatter dot plot of the lymphocyte (L), monocyte (M) and granulocyte (G) populations from a mink with a normal lymphocyte count at day 0 and (c) with a transient drop in the lymphocyte count on day 6 after challenge



**Fig. 4** CDV-N protein detection by flow cytometry in peripheral blood lymphocytes of vaccinated (pCDV-H/-N;  $n = 3$ ; pVRCDV-H/-N;  $n = 4$ ) or pVR/non-vaccinated mink ( $n = 4$ ) on the indicated days (d) and weeks (w) after challenge with the DK91 strain. Uninfected controls were included ( $n = 3$ ). Viral antigen quantification was performed on gated lymphocyte populations in forward-scatter-versus-side-scatter dot plots (as illustrated in Fig. 3). \* indicates a significant difference between the percentage of CDV-N-positive lymphocytes from pCDV-H/-N- and pVRCDV-H/-N-vaccinated mink and those receiving empty plasmids (pVR) or unvaccinated mink


the currently used vaccine strains [4–6, 8, 11, 12, 14, 24]. The heterogeneity found among CDV vaccine strains and wild-type CDV strains have been speculated to be responsible for the incomplete protection of the vaccinated animals [5, 19, 59].

To assess whether a wild-type DNA vaccine (pVRCDV-H/-N/-F) is more efficacious against wild-type CDV than a DNA vaccine based on an attenuated strain (pCDV-H/-N), the humoral and cellular responses were evaluated in mink. We found that both DNA vaccines were able to prime immunological memory responses. Even though the animals vaccinated with the wild-type plasmids (pVRCDV-H/-N/-F) did not produce an antibody response above 100 prior to challenge, all of the immunized animals, with a single exception, were solidly protected against lymphocyte-associated viremia, multisystemic infection and lymphopenia. One mink that was vaccinated with pVRCDV-H/-N/-F developed transient lymphopenia. Importantly, the vaccine regimens tested in the present study induced a comparable protective immunity measured as VN antibodies and IFN-producing lymphocytes against wild-type CDV. It can still not be ruled out that the sequence variations between the H genes of vaccine and circulating wild-type strains can contribute to inadequate immunity in some vaccinated animals.

Our study indicates that both VN antibodies and cell-mediated memory responses contribute to protection against CDV. The relative contribution of VN antibodies and cell-mediated memory responses to protection remains unclear. However, to achieve solid disease protection against CDV and MeV, both cell-mediated and VN antibody responses must be induced by the vaccines [35, 36, 38, 53]. An advantage of the DNA vaccines is that there is no risk of vaccine-induced disease from residual virulence, which must be considered in the case of attenuated live vaccines, as illustrated by the formerly used vaccine based on the Rockborn strain [31]. The Rockborn vaccine was used globally from 1962 to the mid-1990s, when it was withdrawn as a consequence of several reported suspected cases of severe vaccine-induced disease (e.g., post-vaccinal encephalitis) in dogs who had received the less-attenuated vaccine [31].

In the current study, 10- to 12-month-old mink were immunized four times with different combinations of plasmids encoding the H, N and F genes from CDV. The DNA vaccines were administered by the intradermal and intramuscular routes, as this combination had previously been found to induce higher levels of serum antibodies than the intramuscular route alone [44, 46]. By combined intradermal and intramuscular injections, both Langerhans cells and myocytes can be primed. Furthermore, this allows a sufficient volume of plasmids to be injected, since only a relatively small volume of DNA vaccine can be administered





**Fig. 5** IFN- $\gamma$ -producing lymphocytes from vaccinated mink with pCDV-H/-N ( $n = 3$ ) (a) or with pVRCDV-H/-N ( $n = 4$ ) (b), from mink receiving empty plasmids (pVR) or non-vaccinated mink ( $n = 4$ ) (c), and from uninfected control mink ( $n = 3$ ) (d) on the indicated days (d) and weeks (w) after challenge. Corresponding IFN- $\gamma$  and IgG antibody staining profiles of cells within a combined lymphocyte/monocyte gate of an individual mink are included. The

lymphocyte/monocyte gates were identical to the one shown in Fig. 3. The horizontal dotted lines indicate the average background level of IFN- $\gamma$ -producing lymphocytes estimated from the control mink. \* indicates a significant difference between the percentage of IFN- $\gamma$ -producing lymphocytes from pCDV-H/-N- and pVRCDV-H/-N-vaccinated mink and those receiving empty plasmids (pVR) or unvaccinated mink

intradermally. This study showed a strong antibody-based memory response in the DNA-vaccinated mink. Already after two immunizations, all of the animals vaccinated with the pCDV-H and pCDV-N plasmids had medium levels of serum VN antibodies. In contrast, animals receiving the wild-type DNA vaccines had only a limited level of serum

VN antibodies. The nucleotide sequences of the open reading frames (ORF) of the DK91 H, N and F genes are 92.1 %, 93.9 % and 91.3 % identical, respectively, to those of the corresponding ORFs of the Onderstepoort vaccine strain. These sequence differences may affect the neutralization titer obtained, as the Vero-cell-adapted Onderstepoort

vaccine virus was used in the VN antibody assay [28, 60]. Therefore, in further studies, it would be preferable to test serum samples for neutralizing activity against the homologous wild-type virus from which the relevant vaccine is generated to clarify whether the low antibody levels might be due to an antigenic difference between the CDV strains. However, in the present study we were able to show that both DNA vaccines induced a solid neutralizing antibody response in mink after challenge. Moreover, a previous *in vitro* study has shown that the sequence difference between wild-type and vaccine strains did not have any significant influence on the cross-reactivity of CDV-positive sera in neutralizing assays [9].

The wild-type DNA plasmids (pVRCDV-H/-N/-F) were designed to contain the H, N or F genes (starting 12, 12 and 86 nucleotides upstream of the start codon and ending 55, 31 and 135 nucleotides downstream of the stop codon, respectively), while only the ORFs of Onderstepoort H and N were inserted into the plasmids (pCDV-H/-N). Both expression plasmids contained the cytomegalovirus (CMV) promoter. The extra Kozak nucleotides in the pVRCDV-H/-N/-F may have an influence on the expression of the proteins. For DNA vaccines, it is essential to prime antigen-presenting cells to present the antigens on both MHC I and MHC II to T cells. In addition to the ability of the plasmids to express the antigen *in vivo*, other factors such as post-translational modification can have an influence on the presentation of the antigen on the antigen-presenting cells [61].

The F gene was included in the DNA vaccine with the wild-type strain to assess if it induced a stronger overall immune response. In the present study, the VN antibody levels of the two groups of mink receiving pVRCDV-H/-N or pVRCDV-H/-N/-F were found to be comparable, without any significant differences. In future studies, it will be interesting to evaluate the contribution of F plasmids to the cell-mediated memory response. In this study, immunization with plasmids encoding the H and N genes primed a cell-mediated memory response, as shown by an early increase in the percentage of IFN- $\gamma$ -producing lymphocytes.

We observed no overt clinical signs of distemper, which is in contrast to a previous experiment in 6-month-younger mink infected with the wild-type CDV strain DK91 [46]. The reason for this lack of clinical symptoms is most likely the different doses of challenge material used (a tenfold lower challenge dose was used in the present study), although the lack of clinical symptoms could also be attributed to the age of the animals, as young animals are more susceptible to severe disease, than older ones [58, 62–65]. However, the extent of lymphopenia and lymphocyte-associated CDV N antigen found in the pVR/non-vaccinated group corresponds to data obtained in our previous studies [46, 47]. Our finding of a protective immune

response in DNA-vaccinated mink against challenge with a virulent strain of CDV encourages further studies. It is important to test the DNA vaccines further against a challenge that induces overt clinical signs in unvaccinated animals.

In summary, these results demonstrated induction of VN antibody and cell-mediated (IFN- $\gamma$ ) immune responses in DNA-vaccinated mink compared to pVR/non-vaccinated mink after challenge with wild-type CDV. An immunological memory response was observed in all of the DNA-immunized animals, and the vaccine-induced immunity provided long-term protection against CDV challenge. Our results showed cross-protection between DNA vaccines based on the vaccine strain against wild-type CDV challenge. The protective capacity was comparable with that induced by the wild-type vaccine. However, the heterogeneity between the currently circulating wild-type and vaccine strains must still be considered in future vaccine strategies against CDV to ensure cross-protection. One approach to minimize potential vaccine failures due to genetic and antigenic differences between attenuated strains used to generate the DNA-vaccines and circulating virulent strains of CDV is to immunize with DNA vaccines containing both the H and more-conserved internal antigens. Immunization with the conserved internal antigens N or matrix protein seems to ensure a broader cross-protection against influenza viruses, which undergo antigenic shift and drift [66].

In perspective, the continuous outbreaks of distemper and the ongoing measles outbreaks in Europe and Africa illustrate the need for the development of new, improved vaccines for prophylaxis, and in the case of measles, eventual eradication [67]. The relatively large amount of plasmid DNA and multiple injections used in this study to induce immunity compared to the existing licensed modified live-virus vaccines must be minimized before the DNA vaccines can be used commercially. However, we believe that our finding of a long-term protective effect against wild-type challenge encourages further studies on DNA immunization to reduce the dose of DNA and the number of vaccinations required. One approach to improve the immune response could include immunostimulatory factors like cytokines. Co-administration of a DNA vaccine encoding the MeV H, F and N proteins with an IL-2 molecular adjuvant has been shown to increase the antibody response and the cell-mediated immune response and enhance the level of protection against viremia in newborn macaques [36].

**Acknowledgments** The Danish Fur Breeders Research Fund, The Danish Research Council for Technology and Production (No. 9901640) and University of Copenhagen, are acknowledged for their financial support. The authors wish to thank Leon Langli and Klaus Hartmann for assistance during the animal experiments.

**Conflict of interest** The authors declare that they have no conflict of interest.

## References

1. Faquet CM, Mayo MA, Maniloff J, Desselberger U, Ball LA (2005) Virus taxonomy: the classification and nomenclature of viruses. The eighth report of the International Committee on Taxonomy of Viruses. Elsevier Academic Press, Amsterdam, p 609
2. Greene CE, Appel M (2006) Canine distemper. In: Greene CE (ed) Infectious diseases of the dog and cat. Saunders Elsevier, St. Louis, pp 25–41
3. von Messling V, Milosevic D, Cattaneo R (2004) Tropism illuminated: lymphocyte-based pathways blazed by lethal morbillivirus through the host immune system. *Proc Natl Acad Sci USA* 101(39):14216–14221
4. Benetka V, Leschnik M, Affenzeller N, Möstl K (2011) Phylogenetic analysis of Austrian canine distemper virus strains from clinical samples from dogs and wild carnivores. *Vet Rec* 168(14): 377
5. Blixenkrone-Møller M, Svansson V, Have P, Örvell C, Appel M, Pedersen IR, Dietsz HH, Henriksen P (1993) Studies on manifestations of canine distemper virus infection in an urban dog population. *Vet Microbiol* 37(1–2):163–173
6. Calderon MG, Remorini P, Periolo O, Iglesias M, Mattion N, La TJ (2007) Detection by RT-PCR and genetic characterization of canine distemper virus from vaccinated and non-vaccinated dogs in Argentina. *Vet Microbiol* 125(3–4):341–349
7. Decaro N, Camero M, Greco G, Zizzo N, Tinelli A, Campolo M, Pratelli A, Buonavoglia C (2004) Canine distemper and related diseases: report of a severe outbreak in a kennel. *New Microbiol* 27(2):177–181
8. Ek-Kommonen C, Sihvonen L, Pekkanen K, Rikula U, Nuotio L (1997) Outbreak of canine distemper in vaccinated dogs in Finland. *Vet Rec* 141(15):380–383
9. Haas L, Martens W, Greiser-Wilke I, Mamaev L, Butina T, Maack D, Barrett T (1997) Analysis of the haemagglutinin gene of current wild-type canine distemper virus isolates from Germany. *Virus Res* 48(2):165–171
10. Iwatsuki K, Tokiyoshi S, Hirayama N, Nakamura K, Ohashi K, Wakasa C, Mikami T, Kai C (2000) Antigenic differences in the H proteins of canine distemper viruses. *Vet Microbiol* 71(3–4): 281–286
11. Jozwik A, Frymus T (2002) Natural distemper in vaccinated and unvaccinated dogs in Warsaw. *J Vet Med B Infect Dis Vet Public Health* 49(9):413–414
12. Kapil S, Allison RW, Johnston L 3rd, Murray BL, Holland S, Meinkoth J, Johnson B (2008) Canine distemper viruses circulating in North American dogs. *Clin Vaccine Immunol* 15(4):707–712
13. Simon-Martínez J, Ulloa-Arvizu R, Soriano VE, Fajardo R (2007) Identification of a genetic variant of canine distemper virus from clinical cases in two vaccinated dogs in Mexico. *Vet J* 175(3):423–426
14. Uema M, Ohashi K, Wakasa C, Kai C (2005) Phylogenetic and restriction fragment length polymorphism analyses of hemagglutinin (H) protein of canine distemper virus isolates from domestic dogs in Japan. *Virus Res* 109(1):59–63
15. Martella V, Elia G, Buonavoglia C (2008) Canine distemper virus. *Vet Clin North Am Small Anim Pract* 38(4):787–797
16. Tatsuo H, Ono N, Yanagi Y (2007) Morbilliviruses use signaling lymphocyte activation molecules (CD150) as cellular receptors. *J Virol* 75(13):5842–5850
17. Bolt G, Jensen TD, Gottschalck E, Arctander P, Appel MJ, Buckland R, Blixenkrone-Møller M (1997) Genetic diversity of the attachment (H) protein gene of current field isolates of canine distemper virus. *J Gen Virol* 78(Pt 2):367–372
18. Harder TC, Osterhaus AD (1997) Canine distemper virus—a morbillivirus in search of new hosts? *Trends Microbiol* 5(3): 120–124
19. Martella V, Cirone F, Elia G, Lorusi E, Decaro N, Campolo M, Desario C, Lucente MS, Ballaciccio AL, Blixenkrone-Møller M, Carmichael LE, Buonavoglia C (2006) Heterogeneity within the hemagglutinin genes of canine distemper virus (CDV) strains detected in Italy. *Vet Microbiol* 116(4):301–309
20. Carpenter MA, Appel MJ, Roelke-Parker ME, Munson L, Hofer H, East M, O'Brien SJ (1998) Genetic characterization of canine distemper virus in Serengeti carnivores. *Vet Immunol Immunopathol* 65(2–4):259–266
21. Demeter Z, Lakatos B, Palade EA, Kozma T, Forgach P, Rusvai M (2007) Genetic diversity of Hungarian canine distemper virus strains. *Vet Microbiol* 122(3–4):258–269
22. Harder TC, Kenter M, Appel MJ, Roelke-Parker ME, Barrett T, Osterhaus AD (1995) Phylogenetic evidence of canine distemper virus in Serengeti's lions. *Vaccine* 13(6):521–523
23. McCarthy AJ, Shaw MA, Goodman SJ (2007) Pathogen evolution and disease emergence in carnivores. *Proc Biol Sci* 274(1629):3165–3174
24. Martella V, Elia G, Lucente MS, Decaro N, Lorusso E, Banyai K, Blixenkrone-Møller M, Lan NT, Yamaguchi R, Cirone F, Carmichael LE, Buonavoglia C (2007) Genotyping canine distemper virus (CDV) by a hemi-nested multiplex PCR provides a rapid approach for investigation of CDV outbreaks. *Vet Microbiol* 122(1–2):32–42
25. Blixenkrone-Møller M, Svansson V, Appel M, Krogsrud J, Have P, Örvell C (1992) Antigenic relationships between field isolates of morbilliviruses from different carnivores. *Arch Virol* 123(3–4):279–294
26. Harder TC, Klusmeyer K, Frey HR, Örvell C, Liess B (1993) Intertypic differentiation and detection of intratypic variants among canine and phocid morbillivirus isolates by kinetic neutralization using a novel immunoplaque assay. *J Virol Methods* 41(1):77–92
27. Örvell C, Blixenkrone-Møller M, Svansson V, Have P (1990) Immunological relationships between phocid and canine distemper virus studied with monoclonal antibodies. *J Gen Virol* 71(Pt 9):2085–2092
28. Harder TC, Kenter M, Vos H, Siebelink K, Huisman W, van Amerongen G, Örvell C, Barrett T, Appel MJ, Osterhaus AD (1996) Canine distemper virus from diseased large felids: biological properties and phylogenetic relationships. *J Gen Virol* 77(Pt 3):397–405
29. Ek-Kommonen C, Rudback E, Anttila M, Aho M, Huovilainen A (2003) Canine distemper of vaccine origin in European mink, *Mustela lutreola*—a case report. *Vet Microbiol* 92(3):289–293
30. Henke SE (1997) Effects of modified live-virus canine distemper vaccines in gray foxes. *J Wildlife Rehab* 20(2):3–7
31. Martella V, Blixenkrone-Møller M, Elia G, Lucente MS, Cirone F, Decaro N, Nielsen L, Banyai K, Carmichael LE, Buonavoglia C (2011) Lights and shades on an historical vaccine canine distemper virus, the Rockborn strain. *Vaccine* 29(6):1222–1227
32. Montali RJ, Bartz CR, Teare JA, Allen JT, Appel MJ, Bush M (1983) Clinical trials with canine distemper vaccines in exotic carnivores. *J Am Vet Med Assoc* 183(11):1163–1167
33. Henke A (2002) DNA immunization—a new chance in vaccine research? *Med Microbiol Immunol* 191(3–4):187–190
34. Griot C, Moser C, Cherpillod P, Bruckner L, Wittek R, Zurbriggen A, Zurbriggen R (2004) Early DNA vaccination of

- puppies against canine distemper in the presence of maternally derived immunity. *Vaccine* 22(5–6):650–654
35. Pan CH, Jimenez GS, Nair N, Wei Q, Adams RJ, Polack FP, Rolland A, Vilalta A, Griffin DE (2008) Use of Vaxfectin adjuvant with DNA vaccine encoding the measles virus hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques against measles virus. *Clin Vaccine Immunol* 15(8):1214–1221
  36. Premenko-Lanier M, Rota PA, Rhodes G, Verhoeven D, Barouch DH, Lerche NW, Letvin NL, Bellini WJ, McChesney MB (2003) DNA vaccination of infants in the presence of maternal antibody: a measles model in the primate. *Virology* 307(1):67–75
  37. Premenko-Lanier M, Rota PA, Rhodes GH, Bellini WJ, McChesney MB (2004) Protection against challenge with measles virus (MV) in infant macaques by an MV DNA vaccine administered in the presence of neutralizing antibody. *J Infect Dis* 189(11):2064–2071
  38. Cherpillod P, Tipold A, Griot-Wenk M, Cardozo C, Schimid I, Fatzer R, Schobesberger M, Zurbriggen R, Bruckner L, Roch F, Vandevelde M, Wittek R, Zurbriggen A (2000) DNA vaccine encoding nucleocapsid and surface proteins of wild type canine distemper virus protects its natural host against distemper. *Vaccine* 18(26):2927–2936
  39. Ghosh S, Walker J, Jackson DC (2001) Identification of canine helper T-cell epitopes from the fusion protein of canine distemper virus. *Immunology* 104(1):58–66
  40. Giraudon P, Wild TF (1985) Correlation between epitopes on hemagglutinin of measles virus and biological activities: passive protection by monoclonal antibodies is related to their hemagglutination inhibiting activity. *Virology* 144(1):46–58
  41. Malvoisin E, Wild F (1990) Contribution of measles virus fusion protein in protective immunity: anti-F monoclonal antibodies neutralize virus infectivity and protect mice against challenge. *J Virol* 64(10):5160–5162
  42. Norrby E, Utter G, Örvell C, Appel MJ (1986) Protection against canine distemper virus in dogs after immunization with isolated fusion protein. *J Virol* 58(2):536–541
  43. Örvell C, Sheshberadaran H, Norrby E (1985) Preparation and characterization of monoclonal antibodies directed against four structural components of canine distemper virus. *J Gen Virol* 66(Pt 3):443–456
  44. Dahl L, Jensen TH, Gottschalk E, Karlskov-Mortensen P, Jensen TD, Nielsen L, Andersen MK, Buckland R, Wild TF, Blixenkrone-Møller M (2004) Immunization with plasmid DNA encoding the hemagglutinin and the nucleoprotein confers robust protection against a lethal canine distemper virus challenge. *Vaccine* 22(27–28):3642–3648
  45. Jensen TH, Nielsen L, Aasted B, Blixenkrone-Møller M (2009) Early life DNA vaccination with the H gene of canine distemper virus induces robust protection against distemper. *Vaccine* 27(38):5178–5183
  46. Nielsen L, Søgaard M, Karlskov-Mortensen P, Jensen TH, Jensen TD, Aasted B, Blixenkrone-Møller M (2009) Humoral and cell-mediated immune responses in DNA immunized mink challenged with wild-type canine distemper virus. *Vaccine* 27(35):4791–4797
  47. Nielsen L, Søgaard M, Jensen TH, Andersen MK, Aasted B, Blixenkrone-Møller M (2009) Lymphotropism and host responses during acute wild-type canine distemper virus infections in a highly susceptible natural host. *J Gen Virol* 90(Pt 9):2157–2165
  48. Blixenkrone-Møller M (1989) Detection of intracellular canine distemper virus antigen in mink inoculated with an attenuated or a virulent strain of canine distemper virus. *Am J Vet Res* 50(9):1616–1620
  49. von Messling V, Springfield C, Devaux P, Cattaneo R (2003) A ferret model of canine distemper virus virulence and immunosuppression. *J Virol* 77(23):12579–12591
  50. Nielsen L, Andersen MK, Jensen TD, Blixenkrone-Møller M, Bolt G (2003) Changes in the receptorbinding haemagglutinin protein of wild-type morbilliviruses are not required for adaptation to Vero cells. *Virus Genes* 27(2):157–162
  51. Hartikka J, Sawdey M, Cornefert-Jensen F, Margalith M, Bamhart K, Nolasco M, Vahlsing HL, Meek J, Marquet M, Hobart P, Norman J, Manthorpe M (1996) An improved plasmid DNA expression vector for direct injection into skeletal muscle. *Hum Gene Ther* 17(10):1205–1217
  52. Montgomery DL, Shiver JW, Leander KR, Perry HC, Friedman A, Martinez D, Ulmer JB, Donnelly JJ, Liu MA (1993) Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors. *DNA Cell Biol* 12(9):777–783
  53. Sixt N, Cardoso A, Vallier A, Fayolle J, Buckland R, Wild TF (1998) Canine distemper virus DNA vaccination induces humoral and cellular immunity and protects against a lethal intracerebral challenge. *J Virol* 72(11):8472–8476
  54. Blixenkrone-Møller M, Lunde E, Uttenthal Å (1987) Blood collection in mink. *Scand J Lab Anim Sci* 3:99–100
  55. Barrett T, Visser IK, Mamaev L, Goatley L, van Bresse MF, Osterhaust AD (1993) Dolphin and porpoise morbilliviruses are genetically distinct from phocine distemper virus. *Virology* 193(2):1010–1012
  56. Harslund J, Nielsen OL, Brunner N, Offenberg H (2007) Gender-dependent physiological implications of combined PAI-1 and TIMP-1 gene deficiency characterized in a mouse model. *Am J Physiol Regul Integr Comp Physiol* 293(4):R1630–R1639
  57. Pedersen LG, Castelruiz Y, Jacobsen S, Aasted B (2002) Identification of monoclonal antibodies that cross-react with cytokines from different animal species. *Vet Immunol Immunopathol* 88(3–4):111–122
  58. Appel MJ (1969) Pathogenesis of canine distemper. *Am J Vet Res* 30(7):1167–1182
  59. Lan NT, Yamaguchi R, Inomata A, Furuya Y, Uchida K, Sugano S, Tateyama S (2006) Comparative analyses of canine distemper viral isolates from clinical cases of canine distemper in vaccinated dogs. *Vet Microbiol* 115(1–3):32–42
  60. Mochizuki M, Motoyoshi M, Maeda K, Kai K (2002) Complement-mediated neutralization of canine distemper virus in vitro: cross-reaction between vaccine Onderstepoort and field KDK-1 strains with different hemagglutinin gene characteristics. *Clin Diagn Lab Immunol* 9(4):921–924
  61. Dhama K, Mahendran M, Gupta PK, Rai A (2008) DNA vaccines and their applications in veterinary practice: current perspectives. *Vet Res Commun* 32:341–356
  62. Appel MJ, Gillespie JH (1972) Canine distemper virus. In: Gard S, Hallaver C, Meyer KF (eds) *Virology monographs* 11. Springer, New York, pp 1–96
  63. Bohm J, Blixenkrone-Møller M, Lund E (1989) A serious outbreak of canine distemper among sled-dogs in northern Greenland. *Arctic Med Res* 48(4):195–203
  64. Hansen M, Lund E (1972) The protecting capacity of neutralizing antibodies by distemper virus infections in mink. *Acta Pathol Microbiol Scand B Microbiol Immunol* 80(6):795–800
  65. Krakowka S, Koestner A (1976) Age-related susceptibility to infection with canine distemper virus in gnotobiotic dogs. *J Infect Dis* 134(6):629–632
  66. Berthoud TK, Hamill M, Lillie PJ, Hwenda L, Collins KA, Ewer KJ, Milicic A, Poyntz HC, Lambe T, Fletcher HA, Hill AVS, Gilbert SC (2011) Potent CD8<sup>+</sup> T-cell immunogenicity in humans of novel heterosubtypic influenza A vaccine, MVA-NP + M1. *Clin Infect Dis* 52(1):1–7
  67. Moss WJ, Griffin DE (2011) Measles. *Lancet* 379(9811):153–164